tirzepatide approved for F.D.A. Approves New Obesity Drug That Will Compete With Wegovy Tirzepatide: First Approval | Drugs

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

The FDA says 7% of patients reported anxiety (vs 5% on placebo), but on Reddit, it's frequent (11 mentions), usually described as moderate, and often distressing enough to consider stopping

Diabetes 64(10):34063412 Cukierman-Yaffe T, Gerstein HC, Colhoun HM et al (2020) Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

The most commonly reported adverse events for exenatide and sitagliptin were nausea and diarrhea

The two medications work through different mechanisms, measure doses in different ways, and have completely different dose ranges

Our IV blends can support anything from hydration and immunity to your energy levels and metabolic rate